IL2 and myasthenia gravis: IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12P70, IFN-γ, and IFN-α showed a statistically significant decrease upon reaching minimal manifestations status or better in AChR-antibody positive, non-thymomatous, unstable MG patients.